Zentalis Pharmaceuticals, Inc. Net Income (Loss) Attributable to Noncontrolling Interest
Zentalis Pharmaceuticals, Inc. (ZNTL) reported Net Income (Loss) Attributable to Noncontrolling Interest of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToNoncontrollingInterest · last filed 2026-03-26
- Zentalis Pharmaceuticals, Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2025-12-31 was $0.00.
- Zentalis Pharmaceuticals, Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2025-09-30 was $0.00.
- Zentalis Pharmaceuticals, Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2025-06-30 was $0.00.
- Zentalis Pharmaceuticals, Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2025-03-31 was $0.00.
- Zentalis Pharmaceuticals, Inc. net income (loss) attributable to noncontrolling interest for fiscal 2025 was $0.00.
- Zentalis Pharmaceuticals, Inc. net income (loss) attributable to noncontrolling interest for fiscal 2024 was -$28.00K.
- Zentalis Pharmaceuticals, Inc. net income (loss) attributable to noncontrolling interest for fiscal 2023 was -$114.00K.
- Zentalis Pharmaceuticals, Inc. net income (loss) attributable to noncontrolling interest for fiscal 2022 was -$307.00K.
| Period end | Net Income (Loss) Attributable to Noncontrolling Interest 3 month | Net Income (Loss) Attributable to Noncontrolling Interest 6 month | Net Income (Loss) Attributable to Noncontrolling Interest 9 month | Net Income (Loss) Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $0.00 derived: sum of 2 quarters · filed 2026-03-26 | $0.00 derived: sum of 3 quarters · filed 2026-03-26 | $0.00 10-K · filed 2026-03-26 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-10 | $0.00 derived: sum of 2 quarters · filed 2025-11-10 | $0.00 10-Q · filed 2025-11-10 | $0.00 derived: sum of 4 quarters · filed 2026-03-26 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-06 | $0.00 10-Q · filed 2025-08-06 | $0.00 derived: sum of 3 quarters · filed 2026-03-26 | $0.00 derived: sum of 4 quarters · filed 2026-03-26 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-14 | $0.00 derived: sum of 2 quarters · filed 2026-03-26 | $0.00 derived: sum of 3 quarters · filed 2026-03-26 | $0.00 derived: sum of 4 quarters · filed 2026-03-26 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $0.00 derived: sum of 2 quarters · filed 2026-03-26 | $0.00 derived: sum of 3 quarters · filed 2026-03-26 | -$28.00K 10-K · filed 2026-03-26 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-10 | $0.00 derived: sum of 2 quarters · filed 2025-11-10 | -$28.00K 10-Q · filed 2025-11-10 | -$50.00K derived: sum of 4 quarters · filed 2026-03-26 |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-06 | -$28.00K 10-Q · filed 2025-08-06 | -$50.00K derived: sum of 3 quarters · filed 2026-03-26 | -$62.00K derived: sum of 4 quarters · filed 2026-03-26 |
| 2024-03-31 | -$28.00K 10-Q · filed 2025-05-14 | -$50.00K derived: sum of 2 quarters · filed 2026-03-26 | -$62.00K derived: sum of 3 quarters · filed 2026-03-26 | -$99.00K derived: sum of 4 quarters · filed 2026-03-26 |
| 2023-12-31 | -$22.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$34.00K derived: sum of 2 quarters · filed 2026-03-26 | -$71.00K derived: sum of 3 quarters · filed 2026-03-26 | -$114.00K 10-K · filed 2026-03-26 |
| 2023-09-30 | -$12.00K 10-Q · filed 2024-11-12 | -$49.00K derived: sum of 2 quarters · filed 2024-11-12 | -$92.00K 10-Q · filed 2024-11-12 | -$105.00K derived: sum of 4 quarters · filed 2025-03-26 |
| 2023-06-30 | -$37.00K 10-Q · filed 2024-08-09 | -$80.00K 10-Q · filed 2024-08-09 | -$93.00K derived: sum of 3 quarters · filed 2025-03-26 | -$192.00K derived: sum of 4 quarters · filed 2025-03-26 |
| 2023-03-31 | -$43.00K 10-Q · filed 2024-05-07 | -$56.00K derived: sum of 2 quarters · filed 2025-03-26 | -$155.00K derived: sum of 3 quarters · filed 2025-03-26 | -$190.00K derived: sum of 4 quarters · filed 2025-03-26 |
| 2022-12-31 | -$13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | -$112.00K derived: sum of 2 quarters · filed 2025-03-26 | -$147.00K derived: sum of 3 quarters · filed 2025-03-26 | -$307.00K 10-K · filed 2025-03-26 |
| 2022-09-30 | -$99.00K 10-Q · filed 2023-11-06 | -$134.00K derived: sum of 2 quarters · filed 2023-11-06 | -$294.00K 10-Q · filed 2023-11-06 | -$330.00K derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | -$35.00K 10-Q · filed 2023-08-09 | -$195.00K 10-Q · filed 2023-08-09 | -$231.00K derived: sum of 3 quarters · filed 2023-08-09 | -$6.53M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$160.00K 10-Q · filed 2023-05-10 | -$196.00K derived: sum of 2 quarters · filed 2023-05-10 | -$6.50M derived: sum of 3 quarters · filed 2023-05-10 | -$6.99M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | -$36.00K 10-K · filed 2022-02-24 | -$6.34M derived: sum of 2 quarters · filed 2022-11-09 | -$6.83M derived: sum of 3 quarters · filed 2022-11-09 | -$7.37M 10-K · filed 2024-02-27 |
| 2021-09-30 | -$6.30M 10-Q · filed 2022-11-09 | -$6.79M derived: sum of 2 quarters · filed 2022-11-09 | -$7.33M 10-Q · filed 2022-11-09 | -$7.38M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$488.00K 10-Q · filed 2022-08-09 | -$1.03M 10-Q · filed 2022-08-09 | -$1.08M derived: sum of 3 quarters · filed 2022-08-09 | -$1.19M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$543.00K 10-Q · filed 2022-05-05 | -$596.00K derived: sum of 2 quarters · filed 2022-05-05 | -$706.00K derived: sum of 3 quarters · filed 2022-05-05 | -$1.14M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | -$53.00K 10-K · filed 2022-02-24 | -$163.00K derived: sum of 2 quarters · filed 2022-02-24 | -$598.00K derived: sum of 3 quarters · filed 2022-02-24 | -$707.00K 10-K · filed 2023-03-01 |
| 2020-09-30 | -$110.00K 10-K · filed 2022-02-24 | -$545.00K derived: sum of 2 quarters · filed 2022-02-24 | -$654.00K 10-Q · filed 2021-11-10 | -$694.00K derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | -$435.00K 10-K · filed 2022-02-24 | -$544.00K 10-Q · filed 2021-08-12 | -$584.00K derived: sum of 3 quarters · filed 2022-02-24 | -$812.00K derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | -$109.00K 10-K · filed 2022-02-24 | -$149.00K derived: sum of 2 quarters · filed 2022-02-24 | -$377.00K derived: sum of 3 quarters · filed 2022-02-24 | -$504.00K derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | -$40.00K 10-K · filed 2021-03-25 | -$268.00K derived: sum of 2 quarters · filed 2021-03-25 | -$395.00K derived: sum of 3 quarters · filed 2021-03-25 | -$715.00K 10-K · filed 2022-02-24 |
| 2019-09-30 | -$228.00K 10-K · filed 2021-03-25 | -$355.00K derived: sum of 2 quarters · filed 2021-03-25 | -$675.00K 10-Q · filed 2020-11-09 | |
| 2019-06-30 | -$127.00K 10-K · filed 2021-03-25 | -$447.00K 10-Q · filed 2020-08-13 | ||
| 2019-03-31 | -$320.00K 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |